Researchers test if time to next treatment can replace survival as a cancer trial endpoint
NCT ID NCT03963518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 631 advanced melanoma patients treated with immune checkpoint inhibitors. Researchers wanted to see if the time until a patient needs their next treatment or dies (TNT-D) is a good stand-in for overall survival. The goal was to find a quicker way to measure how well these drugs work in future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
631 people
The number who actually took part.
- Started
-
Jan 2017
- Finished
-
Dec 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
previously untreated advanced melanoma patients included in a recently published clinical trial
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
previously untreated advanced melanoma patients.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced melanoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié, Comprehensive Cancer Center
Bordeaux, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a PET scan find the best tumor site for harvesting Cancer-Fighting cells?
- Can a DNA vaccine teach the immune system to hunt melanoma?
- Can a new biologic drug shrink advanced melanoma tumors?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a diabetes drug boost immunotherapy in advanced melanoma?
- New combo therapy takes on advanced cancers